title: Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction. HGTRI 0103.
abstract: This study will evaluate the safety and efficacy of allogenic donor lymphocyte infusions in patients who have relapsed hematologic malignancies after allogeneic bone marrow transplantation (BMT). Donor lymphocyte transfusions have resulted in the cure of some patients with relapsed leukemia or lymphoproliferative disorder after allogeneic BMT, but has been complicated by the development of graft versus host disease (GvHD). We hypothesize that a retroviral vector containing the Herpes simplex thymidine kinase (HStk) gene will allow for retention of the anti-leukemia response of transfused donor lymphocytes while allowing for the adverse effects of GVHD to be mitigated. Patients with relapsed hematologic malignancies after allogeneic BMT will be infused with ex vivo gene modified donor lymphocytes. The Herpes Simplex thymidine kinase (HStk) gene will be transduced into the cells ex vivo using LTKOSN. 1 vector supernate. Insertion of the HStk gene into lymphocytes confers a sensitivity to the anti-herpes drug ganciclovir (GCV). This selective destruction of donor lymphocytes in situ will be used to abrogate the effect of graft versus host disease, if it develops.
authors.affiliation: Human Gene Therapy Research Institute, Des Moines, IA 50309, USA.
authors.forename: C J
authors.initials: CJ
authors.lastname: Link
authors.forename: R K
authors.initials: RK
authors.lastname: Burt
authors.forename: A E
authors.initials: AE
authors.lastname: Traynor
authors.forename: W R
authors.initials: WR
authors.lastname: Drobyski
authors.forename: T
authors.initials: T
authors.lastname: Seregina
authors.forename: J P
authors.initials: JP
authors.lastname: Levy
authors.forename: L
authors.initials: L
authors.lastname: Gordon
authors.forename: S T
authors.initials: ST
authors.lastname: Rosen
authors.forename: W H
authors.initials: WH
authors.lastname: Burns
authors.forename: B
authors.initials: B
authors.lastname: Camitta
authors.forename: J
authors.initials: J
authors.lastname: Casper
authors.forename: M
authors.initials: M
authors.lastname: Horowitz
authors.forename: M
authors.initials: M
authors.lastname: Juckett
authors.forename: C
authors.initials: C
authors.lastname: Lawton
authors.forename: D
authors.initials: D
authors.lastname: Margolis
authors.forename: D
authors.initials: D
authors.lastname: Pietryga
authors.forename: P
authors.initials: P
authors.lastname: Rowlings
authors.forename: C
authors.initials: C
authors.lastname: Taylor
authors.forename: M
authors.initials: M
authors.lastname: Furtado
authors.forename: J
authors.initials: J
authors.lastname: Stefka
authors.forename: S
authors.initials: S
authors.lastname: Gupta-Burt
authors.forename: H
authors.initials: H
authors.lastname: Kaiser
authors.forename: D H
authors.initials: DH
authors.lastname: Vesole
mesh_terms: D002985:Clinical Protocols; D005069:Evaluation Studies as Topic; D005822:Genetic Vectors; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000009:adverse effects / Q000379:methods*; D007945:Leukemia, Lymphoid / Q000628:therapy*; D008214:Lymphocytes / Q000166:cytology / Q000378:metabolism; D018579:Patient Selection; D012074:Remission Induction / Q000379:methods; D018139:Simplexvirus / Q000201:enzymology; D013937:Thymidine Kinase / Q000235:genetics* / Q000378:metabolism
chemical_list: D013937:Thymidine Kinase